| Literature DB >> 10220142 |
P Legoix1, M F Legrand, E Ollagnon, G Lenoir, G Thomas, J Zucman-Rossi.
Abstract
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder that predisposes to nervous system tumors. Point mutations are evidenced in about 50% of the NF2 patients and large genomic deletions account for approximately 33% of the NF2 gene alterations. To facilitate the deletion screening, 16 polymorphic markers were identified in the NF2 genomic sequence enabling an hemizygosity test in familial studies.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10220142 DOI: 10.1002/(SICI)1098-1004(1999)13:4<290::AID-HUMU5>3.0.CO;2-C
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878